Objectives: To investigate the in vitro activity of olorofim (F901318), a novel broad-spectrum antifungal agent, against 150 strains belonging to 16 different cryptic species of Aspergillus by EUCAST and CLSI methodologies.
Introduction
Aspergillus spp. are some of the most common opportunistic human pathogens worldwide, especially in immunocompromised patients. They are the most frequent moulds isolated in clinical samples 1 and can produce a wide range of infections, such as invasive aspergillosis, chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis. The leading cause of these lifethreatening infections is Aspergillus fumigatus (85%), followed by Aspergillus flavus (5%-10%), Aspergillus terreus (2%-10%) and Aspergillus niger (2%-3%). 2 However, the advances of molecular tools for identification during the last decade have led to the description of new species within the genus Aspergillus that are considered cryptic or sibling because they are difficult to differentiate by classical methods. Their prevalence in the clinical setting has been reported to be between 11% and 19% in three studies. [3] [4] [5] It has been recommended that Aspergillus isolates should be classified to the 'species complex' level, 6 as a way of gathering all these closely related cryptic species if appropriate speciation techniques are not performed. These species are important in the clinical setting because of their susceptibility profile, as azoles and amphotericin B frequently show poor activity against them, and some are considered to be MDR. 3, 7 Therefore, new antifungal drugs that act via novel mechanisms are needed to overcome this ever-growing problem of resistance to current therapies.
The orotomides are a new chemical class of drugs whose most representative antifungal is olorofim (F901318). This synthetic small molecule inhibits dihydroorotate dehydrogenase (DHOH), which catalyses the conversion of dihydroorotate to orotate in the pyrimidine biosynthesis pathway. 8 Although it shows no activity against yeasts and Mucorales, olorofim has potent in vitro efficacy against a broad spectrum of pathogenic moulds such as Coccidioides immitis, Coccidioides posadasii, Histoplasma capsulatum, Blastomyces dermatitidis, Penicillium spp., Scedosporium spp., Fusarium spp. and Aspergillus spp., including azole-resistant A. fumigatus. [8] [9] [10] [11] [12] [13] Murine models of invasive aspergillosis have confirmed the in vivo effect of this compound, indicating good tissue distribution. 8, 14 The aim of this study was to further evaluate the in vitro activity of olorofim and other comparators against a collection of clinical isolates of cryptic species of Aspergillus by comparing the results obtained by standard methodologies for broth microdilution susceptibility testing of antifungal agents (CLSI and EUCAST).
Materials and methods

Isolates
A total of 150 Aspergillus strains belonging to six different species complexes were tested in this study. All strains were obtained from clinical samples and identified to the species level by standard microscopic morphology and by sequencing the internal transcribed spacer (ITS) region of the ribosomal DNA (rDNA) and part of the b-tubulin gene following methods previously reported. 1 
Susceptibility testing
The antifungal susceptibility testing was performed following EUCAST reference method 9.2 15 and CLSI M38-A2. 16 Antifungals used were olorofim (range 0. Table 1 shows the GM, MIC 50 , MIC 90 and range for all the species tested at 48 h of incubation by EUCAST and CLSI methods with amphotericin B, voriconazole, posaconazole and olorofim. For micafungin, GM, MEC 50 , MEC 90 and range by species complex tested at 48 h of incubation by EUCAST and CLSI are shown. MIC/MEC 50 and MIC/MEC 90 were only calculated for species that had more than five isolates.
Results
Overall, olorofim was active against all cryptic species of Aspergillus, showing more potent activity than the rest of the antifungals tested both by EUCAST and CLSI for all species complexes.
Regarding A. fumigatus complex, all five species tested showed different resistance patterns to amphotericin B and/or azoles as previously described. 3 Micafungin was active against these (MEC 90 s ranged from 0.015 to 0.25 mg/L by EUCAST and from 0.007 to 0.06 mg/L by CLSI), and olorofim MIC 90 was 0.015 mg/L for each of these (except for Aspergillus lentulus by EUCAST; MIC 90 "0.03 mg/L). Specifically, A. lentulus and Aspergillus fumigatiaffinis have been reported to be highly resistant species, both to amphotericin B and azoles, 3, 17 and olorofim was able to inhibit both species.
Species belonging to the Aspergillus ustus complex have also been described as MDR. 3, 18 MICs of posaconazole and voriconazole ranged from 4 to 16 mg/L by EUCAST and from 2 to 16 mg/L by CLSI for the three species tested, whereas amphotericin B MICs ranged from 0.12 to 2 mg/L by both procedures. Micafungin showed moderate activity (GMs ranged from 0.063 to 0.311 mg/L by both methodologies), but olorofim was the most active compound against these species (GMs were lower than 0.196 mg/L by both methodologies). The four species tested belonging to the A. terreus complex were inhibited by olorofim (GMs ranged from 0.015 to 0.019 mg/L by both methodologies), with micafungin showing high activity as well (GMs were 0.015 mg/L). Voriconazole and posaconazole showed moderate activity against these species, whereas amphotericin B showed high MICs against them (MIC values ranged from 0.12 to 8 mg/L by both methodologies).
Aspergillus ochraceus showed an olorofim MIC 90 of 0.03 mg/L by EUCAST and all isolates tested had an olorofim MIC of 0.015 mg/L by CLSI. Amphotericin B was inactive against this species (MIC 90 "32 mg/L by both methodologies), azoles were moderately active (MIC 90 "0. 
Discussion
Several studies have been carried out since the description of olorofim, demonstrating the in vitro activity of this compound. It has shown activity against Lomentospora prolificans isolates, being the only active compound described thus far against this species. When checked against Scedosporium species, olorofim yielded similar results to voriconazole but was more active than the rest of the drugs tested, 12 including isavuconazole. 9 Its effectiveness has also been assessed against Coccidioides isolates in vitro and in vivo with promising results. 13 Olorofim has been proved to be active in vitro against azoleresistant A. fumigatus (harbouring cyp51A-associated point mutations and without known resistance mechanisms) 8, 10 and has also been reported to be active in vivo in murine models of invasive pulmonary aspergillosis caused by an isolate carrying the TR34/L98H mutation in Cyp51A. 8 The pharmacodynamics of olorofim against A. flavus have also been recently described to be comparable with those from other azole drugs after studying in vitro and in vivo models of sinopulmonary invasive aspergillosis caused by this fungus. 14 This new drug has also displayed in vitro activity against other common Aspergillus species, such as Aspergillus nidulans, A. terreus and A. niger. 
Continued
Activity of olorofim against cryptic species of Aspergillus
In this work, the strong activity of olorofim has also been confirmed against cryptic species of Aspergillus, including those species that show intrinsic resistance to amphotericin B and/or azoles, such as A. lentulus or Aspergillus calidoustus, olorofim being the only drug of those tested with an inhibitory effect against all strains tested. Although micafungin had activity against most of the species tested, the routine use of echinocandins is not recommended as monotherapy for the treatment of invasive aspergillosis or other Aspergillus species because of their distinct mechanism of action, and their use is preferred in combination with other antifungals. 19 CLSI showed, in general, lower MICs (one or two dilutions) than EUCAST. The size of the inocula (10 times lower in CLSI) and the composition of the media (less glucose in CLSI) could explain these discrepancies in the results between the two methodologies used. 20, 21 Further development of this new antifungal is warranted, as well as a multicentre study to evaluate the reproducibility of olorofim activity against moulds and to establish breakpoints and epidemiological cut-off values (ECOFFs) for these species.
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